Abstracts tagged "belimumab and systemic lupus erythematosus (SLE)"

Abstract Number: 742 • 2016 ACR/ARHP Annual Meeting
A Pivotal Phase III, Randomized, Placebo-Controlled Study of Belimumab in Patients with Systemic Lupus Erythematosus Located in China, Japan, and South Korea
Fengchun Zhang¹, Sang-Cheol Bae², Damon Bass³, Myron Chu³, Sally Egginton⁴, David Gordon³, David Roth³, Yoshiya Tanaka⁵ and Jie Zheng⁶, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, The Republic of, ³GSK, Philadelphia, PA, ⁴GSK, Stevenage, United Kingdom, ⁵University of Occupational and Environmental Health, Kitakyushu, Japan, ⁶Ruijin Hospital affiliated to Shanghai Jiao Tong University, Shanghai, China
Background/Purpose: SLE is an autoimmune disease associated with elevated levels of B Lymphocyte Stimulator (BLyS). This study assessed the efficacy and safety of belimumab (BLyS-specific…
Abstract Number: 775 • 2016 ACR/ARHP Annual Meeting
Evaluation of Use of Belimumab in Clinical Practice Settings: Results in Argentina
Alejandra Babini¹, Mercedes Argentina García², Juan Carlos Barreira³, Bernado Pons-Estel⁴, Melitza Iglesias⁵ and Gabriela Streger⁶, ¹Hospital Italiano de Cordoba, Cordoba, Argentina, ²Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, ³Hospital Britanico, Buenos Aires, Argentina, ⁴Sanatorio Parque, Rosario, Argentina, ⁵Medical Affairs, GlaxoSimthKline, Philadelphia, PA, ⁶Direccion Medica, GlaxoSmithKline, Buenos Aires, Argentina
Background/Purpose: Studying clinical effectiveness of belimumab treatment in real world clinical practice of Systemic Lupus Erythematosus (SLE) is relevant in assessing external validity of randomized…
Abstract Number: 735 • 2015 ACR/ARHP Annual Meeting
Belimumab Reduces the Frequency of Flares and Prevents Damage Progression in SLE Patients: Experience in a Clinical Practice Setting
Luca Iaccarino¹, Silvano Bettio¹, Rossella Reggia², Margherita Zen³, Micol Frassi², Laura Andreoli², Linda Nalotto¹, Mariele Gatto¹, Lara Pea², Nicola Bassi¹, Maddalena Larosa¹, Alessandra Zanola², Leonardo Punzi⁴, Angela Tincani² and Andrea Doria¹, ¹Department of Medicine-DIMED, University of Padova, Padova, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ³Division of Rheumatology, University of Padova, Padova, Italy, ⁴Unit of Rheumatology, University of Padova, Padova, Italy
Background/Purpose: To investigate the efficacy and safety of belimumab in patients affected with active systemic lupus erythematosus (SLE) refractory to standard therapy. Methods: Fifty-eight patients,…
Abstract Number: 760 • 2015 ACR/ARHP Annual Meeting
Impact of Baseline Concomitant Medication Use on Belimumab Efficacy and Safety in Patients with Systemic Lupus Erythematosus (SLE)
Andreas Schwarting¹, Mary Anne Dooley², David Roth³, Lisa Edwards⁴, April Thompson⁴ and Barbara Wilson⁴, ¹ACURA Kliniken, Bad Kreuznach, Germany, ²University of North Carolina, Chapel Hill, NC, ³GlaxoSmithKline, King of Prussia, PA, ⁴GlaxoSmithKline, Chapel Hill, NC
Background/Purpose: Belimumab is licensed as add-on therapy to standard lupus care (SoC) in patients with active SLE. Physicians have inquired about the efficacy and safety…
Abstract Number: 1113 • 2015 ACR/ARHP Annual Meeting
B Cell Signature Profiling in Systemic Lupus Erythematosus Patients on Belimumab
Michelle T. Ngo¹, Abigail Benitez², Kimberly J. Payne², Michael De Vera³, Terry Ann Milford² and Karina Marianne D. Torralba⁴, ¹Rheumatology, Loma Linda University, Loma Linda, CA, ²Loma Linda University, Loma Linda, CA, ³Transplant Surgery, Loma Linda University, Loma Linda, CA, ⁴Division of Rheumatology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA
Background/Purpose: The B cell pool is composed of subsets with different phenotypes and functions that mainly have effector functions to maintain immunologic tolerance. These…
Abstract Number: 671 • 2014 ACR/ARHP Annual Meeting
Belimumab Reduces the Frequency of Flares in Patients with Refractory SLE: DATA from Clinical Practice Setting
Andrea Doria¹, Luca Iaccarino², Silvano Bettio², Micol Frassi³, Laura Andreoli³, Rossella Reggia³, Margherita Zen², Linda Nalotto², Mariele Gatto², Lara Pea³, Leonardo Punzi¹ and Angela Tincani³, ¹Department of Medicine - DIMED, University of Padova, Padova, Italy, ²Department of Medicine-DIMED, University of Padova, Padova, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose To investigate the efficacy and safety of belimumab in patients affected with active systemic lupus erythematosus (SLE) refractory to standard therapy in the clinical…
Abstract Number: 2621 • 2012 ACR/ARHP Annual Meeting
Sustained Disease Improvement and Safety Profile Over 1745 Patient-Year Experience (7 years) with Belimumab in Systemic Lupus Erythematosus Patients
Joan T. Merrill¹, Richard A. Furie², Daniel J. Wallace³, William Stohl⁴, W. Winn Chatham⁵, Arthur Weinstein⁶, James D. McKay, Ellen M. Ginzler⁸, Z. John Zhong⁹, William W. Freimuth⁹ and Michelle Petri¹⁰, ¹Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²North Shore-LIJ Health System, Lake Success, NY, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Washington Hospital Center, Washington, DC, ⁷Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, ⁸Human Genome Sciences, Inc., Rockville, MD, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: To update belimumab safety and efficacy data over 7 y in patients with active SLE. Methods: 449 SLE patients with SELENA-SLEDAI scores ≥4 were enrolled…
Abstract Number: 2246 • 2012 ACR/ARHP Annual Meeting
Real World Experience with Belimumab in the Management of Systemic Lupus Erythematosus (SLE): A Single Center, Observational, Post-Marketing Study
Susan S. Kim¹, Tanya Pavri¹, Kyriakos A. Kirou², Jane Salmon¹ and Doruk Erkan¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY
Background/Purpose: With the recent FDA approval of belimumab, clinicians are faced with adjusting their SLE treatment paradigm. The purpose of this study was to examine…
Abstract Number: 614 • 2012 ACR/ARHP Annual Meeting
Predictors of Systemic Lupus Erythematosus Flares: Baseline Disease Activity and Demographic Characteristics From the Combined Placebo Groups in the Phase 3 Belimumab Trials
Ronald F. van Vollenhoven¹, Michelle Petri², Roger A. Levy³, Sandra V. Navarra⁴, Jill P. Buyon⁵, Z. John Zhong⁶, William W. Freimuth⁶ and Ricard Cervera⁷, ¹Karolinska University Hospital, Stockholm, Sweden, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Internal Medicine, Univ Estado Do Rio De Janeiro, Rio de Janeiro, Brazil, ⁴University of Santo Tomas Hospital, Manila, Philippines, ⁵Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁶Human Genome Sciences, Inc., Rockville, MD, ⁷Autoimmune Diseases, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: Predicting which SLE patients are at increased risk for clinically meaningful flares may be useful in making management decisions. The purpose of this analysis was to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].